HomeHome
 
  • Start page
  • Statistics centre
  • Legal texts

    Legal texts

    Legal texts from the European Patent Office (EPO) in a format optimised for different screen sizes.

    Go to overview 

    • Overview
    • European Patent Convention
      • Overview
      • Archive
    • Official Journal
    • EPC Guidelines
      • Overview
      • Archive
    • PCT-EPO Guidelines
      • Overview
      • Archive
    • Guidelines revision cycle
    • Extension / validation system
    • London Agreement
    • National law relating to the EPC
      • Overview
      • Archive
    • Unitary Patent system
    • National measures relating to the Unitary Patent 

    Hand touching a tablet

    EPC now at your fingertips, on all devices

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • European Inventor Award
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2022 ceremony
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service

    EIA jury

    Meet the European Inventor Award jury

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Start page
  • Statistics centre
  • Legal texts
    • Go back
    • Overview
    • European Patent Convention
      • Go back
      • Overview
      • Archive
        • Go back
        • Overview
        • Documentation on the EPC revision 2000
          • Go back
          • Overview
          • Diplomatic Conference for the revision of the EPC
          • Travaux préparatoires
          • New text
          • Transitional provisions
          • Implementing regulations to the EPC 2000
          • Rules relating to Fees
          • Ratifications and accessions
        • Travaux Préparatoires EPC 1973
    • Official Journal
    • EPC Guidelines
      • Go back
      • Overview
      • Archive
    • PCT-EPO Guidelines
      • Go back
      • Overview
      • Archive
    • Guidelines revision cycle
    • Extension / validation system
    • London Agreement
    • National law relating to the EPC
      • Go back
      • Overview
      • Archive
    • Unitary Patent system
    • National measures relating to the Unitary Patent 
  • News & events
    • Go back
    • Overview
    • European Inventor Award
      • Go back
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2022 ceremony
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
  • Service & support
    • Go back
    • Forms
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
  • Patent Index 2020
7. Examination of novelty
  1. Home
  2. Legal texts
  3. Guidelines for Examination
  4. Table of Contents
  5. Part G
  6. Chapter VI
  7. 7. Examination of novelty
  8. 7.1 First or further medical use of known products
  9. 7.1.1 Products that may be claimed for a further medical use
Print
Facebook Twitter Linkedin Email

7.1 First or further medical use of known products

Overview

7.1.1 Products that may be claimed for a further medical use 

The scope of protection of use-related product claims under Art. 54(5) is limited to the substance or composition in the context of its medical use which confers novelty and non-obviousness, if any, on the claimed product.

This principle applies only to substances and compositions and cannot be extended to other products. A claim directed to a device for an intended medical use (e.g. pacemaker or implantable chemical sensor for use in ...) must be construed as claiming a device which is suitable for that medical use (F‑IV, 4.13).

A product qualifies as a "substance or composition" in the sense of Art. 54(5) if it is the active agent or ingredient in the specific medical use and if the therapeutic effect can be ascribed to its chemical properties (see G 5/83 and T 1758/15). For example, consider a filler material which is injected between a first tissue targeted for radiation treatment and a second sensitive tissue which is desired to be protected from radiation. If the shielding effect of the filler material is achieved by a mere mechanical displacement of the sensitive tissue relative to the target tissue, due to the volume it occupies between the two tissues, the filler material qualifies as a device rather than a substance or composition. On the other hand, if the filler material produced a radiation-reducing effect on the sensitive tissue which could be attributed to its chemical properties, it would be considered as a "substance or composition" in the sense of Art. 54(5).

Previous
Next
Footer - Service & support
Footer - More links
Footer
  • Terms of use
  • Legal notice
  • Data protection and privacy